Catalyst
Slingshot members are tracking this event:
Catalyst Therapeutics (CPRX) Phase 3 trial LMS-003, evaluating the efficacy and safety of Firdapse in patients with Lambert-Eaton Myasthenic syndrome (LEMS), set to complete in second half 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CPRX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2017
Occurred Source:
http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=1036819
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Lms-003, Firdapse, Lambert-eaton Myasthenic Syndrome
